Table 2.
Differences in dDNA Between Groups
| Mean | Median | Samples | Max | Significance | |
|---|---|---|---|---|---|
| Monoinfected (1 sample/patient) | 3.03% | 0.66% | 194 | 52.34% | |
| HIV-1/HBV-coinfected (1 sample/patient) | 2.52% | 1.16% | 92 | 71.76% | p-MW = 0.3227 |
| Monoinfected | 3.20% | 0.63% | 386 | 52.34% | |
| HIV-1/HBV-coinfected | 2.87% | 0.79% | 150 | 71.76% | p-MW = 0.212 |
| Splice | Full-length | ||||
| Monoinfected (absolute values), copies/mL* | 4.48 × 105 | 7.96 × 107 | |||
| HIV-1/HBV-coinfected (absolute values), copies/mL* | 1.89 × 106 | 2.88 × 108 | |||
| p-MW | 0.00069 | 0.0027 | |||
| Mean | Median | Samples | Max | Significance | |
| HBeAg-positive | 2.37% | 0.60% | 135 | 24.84% | |
| HBeAg-negative | 2.35% | 0.40% | 121 | 49.87% | p-MW = 0.39 |
| Basal core promoter (BCP) mutant | 2.56% | 0.59% | 100 | 49.87% | |
| Basal core promoter (BCP) wt | 2.10% | 0.50% | 285 | 28.80% | p-MW = 0.99 |
| Precore (PC) mutant | 1.74% | 0.53% | 76 | 49.87% | |
| Precore (PC) wt | 2.24% | 0.50% | 309 | 24.84% | p-MW = 0.79 |
| Genotype | |||||
| A | 1.96% | 0.40% | 102 | 49.87% | |
| B | 1.61% | 0.66% | 48 | 11.94% | |
| C | 3.90% | 0.39% | 123 | 71.76% | |
| D | 2.09% | 0.68% | 121 | 43.10% | |
| E | 3.65% | 3.65% | 2 | 4.16% | |
| G | 1.80% | 1.39% | 8 | 4.34% | |
| Antiviral drug-naive | 4.37% | 0.61% | 108 | 71.76% | |
| Antiviral drug-treated | 4.44% | 1.37% | 147 | 52.34% | p-MW = 0.14+ |
| LMV/FTC-treated (monoinfected) | 6.32% | 3.23% | 77 | 52.34% | p-MW = 0.033+ |
| LMV/FTC-treated (HIV/HBV-coinfected) | 0.43% | 0.35% | 8 | 1.02% | p-MW = 0.19+ |
| LMV/FTC-treated (combined) | 5.77% | 2.88% | 85 | 52.34% | p-MW = 0.093+ |
| Tenofovir-treated (HIV/HBV-coinfected) | 2.55% | 0.34% | 10 | 7.47% | p-MW = 0.59+ |
| Decompensated liver disease, CP > A | 2.63% | 0.49% | 26 | 28.80% | |
| Compensated liver disease, CP = A | 2.58% | 0.44% | 47 | 49.87% | p-MW = 0.58 |
| Advanced fibrosis (Metavir F score 3 and 4) | 2.89% | 0.85% | 69 | 29.71% | |
| Limited or no fibrosis (Metavir F score 0, 1, and 2) | 2.21% | 0.38% | 120 | 31.54% | p-MW = 0.18 |
| Single sample per patient | |||||
| Advanced fibrosis (Metavir F score 3 and 4) | 4.61% | 2.62% | 36 | 29.71% | |
| Limited or no fibrosis (Metavir F score 0, 1, and 2) | 2.89% | 0.64% | 79 | 31.54% | p-MW = 0.096 |
*
Bold denotes significance and was determined by the Mann-Whitney U test for independent nonparametric samples. Attempts to normalize with log transformation failed a Shapiro-Wilk test for an expected normal distribution.
+
Significance value compared to antiviral drug-naïve.